Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1977 2
1979 1
1980 1
1981 1
1982 1
1987 1
1989 2
1990 1
1991 2
1992 3
1993 3
1995 2
1996 3
1997 4
1999 3
2000 4
2001 8
2002 3
2003 5
2004 4
2005 7
2006 2
2007 9
2008 8
2009 14
2010 3
2011 5
2012 7
2013 3
2014 13
2015 23
2016 13
2017 6
2018 14
2019 10
2020 7
2021 14
2022 16
2023 7
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Indications for Growth Hormone Therapy.
Danowitz M, Grimberg A. Danowitz M, et al. Adv Pediatr. 2022 Aug;69(1):203-217. doi: 10.1016/j.yapd.2022.03.005. Epub 2022 Jun 17. Adv Pediatr. 2022. PMID: 35985710 Free PMC article. Review.
In the United States, there are 8 Food and Drug Administration (FDA)-approved indications for pediatric GH therapy: GH deficiency, Prader-Willi Syndrome, small for gestational age (SGA) without catch-up growth, idiopathic short stature, Turner syndrome, SHOX gene haploinsufficien …
In the United States, there are 8 Food and Drug Administration (FDA)-approved indications for pediatric GH therapy: GH deficiency, Prader-Wi …
Encephalocraniocutaneous Lipomatosis.
Bavle A, Shah R, Gross N, Gavula T, Ruiz-Elizalde A, Wierenga K, McNall-Knapp R. Bavle A, et al. J Pediatr Hematol Oncol. 2018 Oct;40(7):553-554. doi: 10.1097/MPH.0000000000001170. J Pediatr Hematol Oncol. 2018. PMID: 29683947
Targeted sequencing of tissue from the right gluteal mass, revealed a mosaic activating FGFR1 c.1966A>G (p.Lys656Glu) mutation, absent in normal left gluteal tissue, confirming the diagnosis of encephalocraniocutaneous lipomatosis (ECCL), belonging to the family of RASopathies …
Targeted sequencing of tissue from the right gluteal mass, revealed a mosaic activating FGFR1 c.1966A>G (p.Lys656Glu) mutation, absent in …
Approach to the Patient: Safety of Growth Hormone Replacement in Children and Adolescents.
Bamba V, Kanakatti Shankar R. Bamba V, et al. J Clin Endocrinol Metab. 2022 Feb 17;107(3):847-861. doi: 10.1210/clinem/dgab746. J Clin Endocrinol Metab. 2022. PMID: 34636896 Review.
Methods to mitigate risk will be reviewed. Finally, this information will be applied to each clinical case, highlighting differences in counseling and clinical outcomes. rhGH therapy has been used for more than 3 decades. ...
Methods to mitigate risk will be reviewed. Finally, this information will be applied to each clinical case, highlighting differences …
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH, Chen Z, Cooke VG, Dobson JR, Deng Z, Fei F, Firestone B, Fodor M, Fridrich C, Gao H, Grunenfelder D, Hao HX, Jacob J, Ho S, Hsiao K, Kang ZB, Karki R, Kato M, Larrow J, La Bonte LR, Lenoir F, Liu G, Liu S, Majumdar D, Meyer MJ, Palermo M, Perez L, Pu M, Price E, Quinn C, Shakya S, Shultz MD, Slisz J, Venkatesan K, Wang P, Warmuth M, Williams S, Yang G, Yuan J, Zhang JH, Zhu P, Ramsey T, Keen NJ, Sellers WR, Stams T, Fortin PD. Chen YN, et al. Nature. 2016 Jul 7;535(7610):148-52. doi: 10.1038/nature18621. Epub 2016 Jun 29. Nature. 2016. PMID: 27362227
Activating mutations of SHP2 have been associated with developmental pathologies such as Noonan syndrome and are found in multiple cancer types, including leukaemia, lung and breast cancer and neuroblastoma. ...
Activating mutations of SHP2 have been associated with developmental pathologies such as Noonan syndrome and are found in mult …
Endocrinological manifestations in RASopathies.
Tamburrino F, Scarano E, Schiavariello C, Perri A, Pession A, Mazzanti L. Tamburrino F, et al. Am J Med Genet C Semin Med Genet. 2022 Dec;190(4):471-477. doi: 10.1002/ajmg.c.32013. Epub 2022 Nov 19. Am J Med Genet C Semin Med Genet. 2022. PMID: 36401574 Review.
Noonan syndrome: rhGH treatment and PTPN11 mutation.
Wu X, Wu J, Yuan Y, Yang L, Yu L. Wu X, et al. Mol Genet Genomic Med. 2023 Nov;11(11):e2266. doi: 10.1002/mgg3.2266. Epub 2023 Aug 1. Mol Genet Genomic Med. 2023. PMID: 37525886 Free PMC article.
OBJECTIVE: To analyze the clinical data and genetic characteristics of Noonan syndrome, both the effect and side effects of recombinant human growth hormone (rhGH) treatment. METHODS: We collected clinical data from 8 children with Noonan syn …
OBJECTIVE: To analyze the clinical data and genetic characteristics of Noonan syndrome, both the effect and side effect …
Efficacy and safety of growth hormone therapy in children with Noonan syndrome.
Sodero G, Cipolla C, Pane LC, Sessa L, Malavolta E, Arzilli F, Leoni C, Zampino G, Rigante D. Sodero G, et al. Growth Horm IGF Res. 2023 Apr-Jun;69-70:101532. doi: 10.1016/j.ghir.2023.101532. Epub 2023 Apr 9. Growth Horm IGF Res. 2023. PMID: 37084633 Free article. Review.
Patients with Noonan syndrome typically have a target height <2 standard deviations compared to the general population, and half of the affected adults remain permanently below the 3rd centile for height, though their short stature might result from a multifactor …
Patients with Noonan syndrome typically have a target height <2 standard deviations compared to the general population, and …
Chiari I malformation in patients with RASopathies.
Han Y, Chen M, Wang H. Han Y, et al. Childs Nerv Syst. 2021 Jun;37(6):1831-1836. doi: 10.1007/s00381-020-05034-2. Epub 2021 Jan 6. Childs Nerv Syst. 2021. PMID: 33409618 Review.
However, it is not always clear whether the observed associations between CIM and RASopathies are real or random. The knowledge of the real association could provide useful guidance to clinicians. ...METHOD AND RESULTS: We reviewed the current knowledge of CIM and RASopath …
However, it is not always clear whether the observed associations between CIM and RASopathies are real or random. The knowledge of th …
Syndromic disorders with short stature.
Şıklar Z, Berberoğlu M. Şıklar Z, et al. J Clin Res Pediatr Endocrinol. 2014;6(1):1-8. doi: 10.4274/Jcrpe.1149. J Clin Res Pediatr Endocrinol. 2014. PMID: 24637303 Free PMC article. Review.
In this review, the relatively more frequently seen syndromes with short stature (Noonan syndrome, Prader-Willi syndrome, Silver-Russell syndrome and Aarskog-Scott syndrome) were discussed. ...
In this review, the relatively more frequently seen syndromes with short stature (Noonan syndrome, Prader-Willi syndrome, Silv …
221 results